Tweets
N. Zealand study shows their cost of knee OA was $200 million in 2013; and without any changes in the standards of care, this isprojected to increase to $370 million by 2038. (includes an additional 4,000 TKRs per year by 2038). https://t.co/B1awh1ky1B
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
Claims study of RA, PsA, AS/SpA patients on TNF inhibitors shows a comparison of 31,527 MTX vs 34,651 TNFi initiators. MTX was D/C sooner in PsA & AS [aHR 1.10, 1.23) vs RA pts. Concomitant MTX reduced risk of TNFi D/C in all [aHR 0.85, 0.81, 0.79] https://t.co/0l2J2FDsUm
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
Might Vioxx make a backdoor comeback? 2017 Vioxx went off patent, now a small pharma has applied to the FDA for orphan drug approval of rofecoxib (& etoricoxib) to treat hemophiliac arthropathy (large unmet need). Say it aint so! https://t.co/kENHHhcyIT https://t.co/QpDNiaCZyz
Links:
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
Choi and colleagues have shown that allopurinol-associated severe cutaneous adverse reactions are higher with Heart (RR 1.44) and Renal (11 fold) disease. Initating low-dosage allopurinol may substantially mitigate this risk. https://t.co/gyj7Xn3uhx
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
MotherToBaby Pregnancy Study in 528 RA pts has shown oral steroid use yields a dose dependent risk of pre-term birth. PTB was increased high dose (RR: 4.77) and medium dose (aRR: 1.81) OCS in the 1st 139 gestational days; DMARDs/biologics were not https://t.co/cuggovK8eL
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
Analysis of retail pharmacies and drug costs show that, compared to large chain pharmacies, big box was 48% cheaper, followed by grocery-based (18% cheaper), next small chain (51% higher), and independent pharmacies (61% higher) https://t.co/jlQnNboiAR
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
Approximately 20–30% of IBD patients will develop spondyloarthritis. Using a survey tool on 244 IBD pts they found 21% with sufficient criteria to suspect SpA - Other risk factors included being female, Crohn's, prior DMARD or biologic drug use. https://t.co/9Ail7syLmB
Links:
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
One of my favorite things about writing "health humanities" pieces for journals are the gracious, thoughtful, insightful notes I get from fellow docs. This one arrived in my inbox this AM. Humbling in its perfection.
In response to this article: https://t.co/9uPvPDOPAI https://t.co/85usMOPqlb
Adam Cifu @adamcifu ( View Tweet )
6 years 10 months ago
Felt the need to update my 10 commandments. Fortunately, on twitter, commandments are not written in stone. https://t.co/Rt9YDW8lFh
Adam Cifu @adamcifu ( View Tweet )
6 years 10 months ago
"Physicians don’t hate technology – they have smartphones, fitness trackers and tablets just like everyone else – what they hate is bad technology."
Truth. #fightburnout
https://t.co/qTG0jZFtDL
Gabe Charbonneau, MD @gabrieldane ( View Tweet )
6 years 10 months ago
Survey for Rheumatologists - You would use an MRI in an RA to assess what?
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
Kaiser study of 1956 SLE patients shows only 58% of were adherent (≥ 80%) to hydroxychloroquine; not predicted by the Rheum, hospital or socioeconomics. Risk factors for nonadherence included age, being white, # of Rheum visits/yr. https://t.co/qRdJRGvRAr
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
Retrospective claims study shows that higher ACPA and RF titers were independently associated with 60-78% increased mortality in established RA; the association persisted in when Rx with DMARDs, but not with biologics. https://t.co/hHJx4alNIQ
Links:
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
Study of 101 RA pts w/ baseline Cardiac CT; after median of 83 mos, 48% had progression of plaque; predicted by older age, inflammation & prednisone (p<0.05). Coronary Art. Calcium progressors were older, obese, HTN w/ more inflammation https://t.co/hJRhfja0yk
Links:
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
Tofacitinib therapy is being studied (not yet approved) in several dermatologic conditions - psoriasis, alopecia areata/universalis, vitiligo, atopic dermatitis and dermatomyositis. https://t.co/Ez3u95Eh7K
Dr. John Cush @RheumNow ( View Tweet )
6 years 10 months ago
